The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting
- PMID: 23318473
- DOI: 10.1016/j.yebeh.2012.11.052
The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting
Abstract
In this retrospective controlled study, the impact of adjunctive lacosamide (LCM) on cognition in patients with epilepsy was evaluated and compared with that of topiramate (TPM) and lamotrigine (LTG) in a naturalistic outpatient setting. Cognition was investigated by means of objective assessment of executive functions (EpiTrack®) and verbal memory and by subjective ratings of self-perceived side effects (cognition, mood, and vegetative). Quality of life was assessed using the QOLIE-10 questionnaire. Patients underwent assessment at baseline and after a median follow-up interval of 32 weeks. Forty-four patients were treated with LCM, 11 with LTG, and 15 with TPM. Treatment arms differed with regard to the age at onset of epilepsy (LTG>TPM) and to seizure control from baseline to follow-up, which was best in patients whose seizures were treated with LTG (55% vs. 16% in patients whose seizures were treated with LCM and 13% in patients whose seizures were treated with TPM). Groups did not differ in the type of epilepsy, daily drug load or drug load change, nor in baseline seizure frequency. Repeated measures statistics controlling for epilepsy onset and seizure outcome showed deteriorated executive functions with TPM (F=7.5, p=0.001). On an individual level (reliable change indices), 53% of the patients whose seizures were treated with TPM showed losses in this domain (LCM 14%, LTG 27%) and none of the patients showed improvement (LCM 23%, LTG 27%; χ(2)=11.8, p=0.019). No differences in memory, quality of life, or mood were noted among patients in the three treatment arms. Subjective cognitive complaints increased in 5 of the 9 patients whose seizures were treated with TPM (LCM 1/9, LTG 0/9; χ(2)=11.9, p=0.025). The findings of this study demonstrate for the first time that the cognitive side effect profile of LCM is comparable to that of LTG and superior to that of TPM. This is indicated by both subjective and objective measures. Given the naturalistic setting and the retrospective nature of the study, a follow-up prospective, randomized trial with larger sample sizes is required to confirm these findings.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting.Seizure. 2018 May;58:141-146. doi: 10.1016/j.seizure.2018.04.015. Epub 2018 Apr 22. Seizure. 2018. PMID: 29704679
-
Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication.Epilepsy Behav. 2004 Oct;5(5):716-21. doi: 10.1016/j.yebeh.2004.06.017. Epilepsy Behav. 2004. PMID: 15380124
-
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.Neurology. 2005 Jun 28;64(12):2108-14. doi: 10.1212/01.WNL.0000165994.46777.BE. Neurology. 2005. PMID: 15985582 Clinical Trial.
-
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis.CNS Drugs. 2023 Oct;37(10):883-913. doi: 10.1007/s40263-023-01029-0. Epub 2023 Aug 17. CNS Drugs. 2023. PMID: 37589821
-
The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy.Epilepsy Behav. 2020 Dec;113:107580. doi: 10.1016/j.yebeh.2020.107580. Epub 2020 Nov 24. Epilepsy Behav. 2020. PMID: 33242771 Review.
Cited by
-
Health-Related Quality of Life and Cognitive Performance During 12-Month Adjunctive Brivaracetam Treatment in Patients with Focal-Onset Seizures: A Prospective, Observational Study in Europe.Neurol Ther. 2025 Apr;14(2):609-625. doi: 10.1007/s40120-024-00698-3. Epub 2025 Feb 20. Neurol Ther. 2025. PMID: 39976892 Free PMC article.
-
Clinical Management of Diffuse Low-Grade Gliomas.Cancers (Basel). 2020 Oct 16;12(10):3008. doi: 10.3390/cancers12103008. Cancers (Basel). 2020. PMID: 33081358 Free PMC article. Review.
-
Cognitive impairment in childhood onset epilepsy: up-to-date information about its causes.Korean J Pediatr. 2016 Apr;59(4):155-64. doi: 10.3345/kjp.2016.59.4.155. Epub 2016 Apr 30. Korean J Pediatr. 2016. PMID: 27186225 Free PMC article. Review.
-
Lamotrigine add-on therapy for drug-resistant focal epilepsy.Cochrane Database Syst Rev. 2020 Mar 20;3(3):CD001909. doi: 10.1002/14651858.CD001909.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2023 Dec 11;12:CD001909. doi: 10.1002/14651858.CD001909.pub4. PMID: 32196639 Free PMC article. Updated.
-
Gliomagenesis, Epileptogenesis, and Remodeling of Neural Circuits: Relevance for Novel Treatment Strategies in Low- and High-Grade Gliomas.Int J Mol Sci. 2024 Aug 16;25(16):8953. doi: 10.3390/ijms25168953. Int J Mol Sci. 2024. PMID: 39201639 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical